

## **EUROPEAN COMMISSION RECOGNISES LIFECARE INNOVATIONS IN IMPLANTABLE GLUCOSE MONITORING**

**Bergen, Norway 12 March 2026 - Lifecare ASA, a MedTech company developing next-generation implantable Continuous Glucose Monitoring (CGM) technology, announces that two innovations developed within the EU-funded FORGETDIABETES project have been published on the European Commission's Innovation Radar platform.**

Lifecare has been recognised as a *Key Innovator* in connection with the following innovations:

- Osmotic pressure-based implantable intra-peritoneal sensor for continuous glucose monitoring
- Method to stabilise Concanavalin A for temperature stability of sensor operation

The Innovation Radar is an initiative of the European Commission that identifies high-potential innovations and innovators emerging from EU-funded research and innovation programmes.

### **Recognition of core platform technology**

The osmotic pressure-based implantable sensor represents the fundamental sensing principle underlying Lifecare's proprietary CGM platform. Unlike traditional enzyme-based CGM systems, the technology leverages osmotic pressure variations to measure glucose levels, enabling a fully implantable and long-duration glucose monitoring solution.

The second recognised innovation relates to stabilisation methods for key biochemical components used within the sensing mechanism. Improved stability of these components supports reliable long-term sensor operation and contributes to the robustness of the sensing platform.

Both innovations have been identified by the European Commission as having potential relevance for future standardisation activities.

### **Supporting technology development**

Lifecare continues the development of its implantable CGM technology, focusing on validating the underlying sensing platform and advancing the system toward future clinical evaluation.

Publication on the Innovation Radar platform highlights the scientific foundation of Lifecare's technology and reflects the contribution of EU-supported research to the advancement of new approaches in glucose monitoring.

“Being recognised as a Key Innovator by the European Commission highlights the strength of the scientific foundation behind our technology”, says Joacim Holter, CEO of Lifecare. “Our focus remains on translating innovation into practical solutions that can contribute to improved glucose monitoring and diabetes management.”

**About us**

Lifecare ASA is a medical sensor company developing technology for sensing and monitoring of various body analytes. Lifecare's focus is to bring the next generation of Continuous Glucose Monitoring systems to market. Lifecare enables osmotic pressure as sensing principle. Lifecare's sensor technology is suitable for identifying and monitoring the occurrence of a wide range of analytes and molecules in the human body and in pets.

**Contacts**

For further information, please contact:

Joacim Holter, CEO, [joacim.holter@lifecare.no](mailto:joacim.holter@lifecare.no), +47 40 05 90 40

Renete Kaarvik, CFO, [renete.kaarvik@lifecare.no](mailto:renete.kaarvik@lifecare.no), +47 94 83 82 42